

1 **Levels and determinants of COVID-19 vaccine hesitancy among sub-Saharan African**
2 **adolescents**

3
4 Dongqing Wang^{1¶*}, Angela Chukwu^{2¶}, Mary Mwanyika-Sando^{3¶}, Sulemana Watara Abubakari⁴,
5 Nega Assefa⁵, Isabel Madzorera¹, Elena C Hemler¹, Abbas Ismail⁶, Bruno Lankoande⁷, Frank
6 Mapendo³, Ourohiré Millogo⁸, Firehiwot Workneh⁹, Temesgen Azemraw⁹, Lawrence G Febir⁴,
7 Christabel James¹⁰, Amani Tinkasimile³, Kwaku Poku Asante⁴, Till Baernighausen^{1,11,12},
8 Yemane Berhane⁹, Japhet Killewo¹³, Ayoade M.J. Oduola¹⁰, Ali Sie⁸, Emily R Smith^{14,15},
9 Abdramane Bassiahi Soura⁷, Raji Tajudeen¹⁶, Said Vuai^{6†}, Wafaie W Fawzi^{1,17,18†*}

10
11 ¹Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
12 Harvard University, Boston, Massachusetts, United States of America

13 ²Department of Statistics, University of Ibadan, Ibadan, Nigeria

14 ³Africa Academy for Public Health, Dar es Salaam, Tanzania

15 ⁴Kintampo Health Research Centre, Research and Development Division, Ghana Health Service,
16 Kintampo North Municipality, Bono East Region, Ghana

17 ⁵College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

18 ⁶College of Natural and Mathematical Sciences, University of Dodoma, Dodoma, Tanzania

19 ⁷Institut Supérieur des Sciences de la Population, University of Ouagadougou, Ouagadougou,
20 Burkina Faso

21 ⁸Nouna Health Research Center, Burkina Faso

22 ⁹Addis Continental Institute of Public Health, Ethiopia

23 ¹⁰University of Ibadan Research Foundation, University of Ibadan, Ibadan, Nigeria

24 ¹¹Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany

25 ¹²Africa Health Research Institute, KwaZulu-Natal, South Africa

26 ¹³Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied
27 Sciences, Dar es Salaam, Tanzania

28 ¹⁴Department of Global Health, Milken Institute School of Public Health, George Washington
29 University, Washington, DC, United States of America

30 ¹⁵Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health,
31 George Washington University, Washington, DC, United States of America

32 ¹⁶Division of Public Health Institutes and Research, Africa Centres for Disease Control and
33 Prevention, Addis Ababa, Ethiopia

34 ¹⁷Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University,
35 Boston, Massachusetts, United States of America

36 ¹⁸Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University,
37 Boston, Massachusetts, United States of America

38

39 ¶ These authors contributed equally to this work as first authors.

40 † These authors contributed equally to this work as last authors.

41

42 * Joint corresponding authors:

43 E-mail: dqwang@hsph.harvard.edu (DW)

44 mina@hsph.harvard.edu (WWF)

45 Short title: COVID-19 vaccine hesitancy in sub-Saharan African adolescents

46

47 **Abstract**

48 COVID-19 vaccine hesitancy among adolescents poses a challenge to the global effort to control
49 the pandemic. This multi-country survey aimed to assess the levels and determinants of COVID-
50 19 vaccine hesitancy among adolescents in sub-Saharan Africa between July and December
51 2021. The survey was conducted using computer-assisted telephone interviewing among
52 adolescents in five sub-Saharan African countries, Burkina Faso, Ethiopia, Ghana, Nigeria, and
53 Tanzania. A rural area and an urban area were included in each country (except Ghana, which
54 only had a rural area), with approximately 300 adolescents in each area and 2803 in total.
55 Sociodemographic characteristics and perceptions and attitudes on COVID-19 vaccines were
56 measured. Vaccine hesitancy was defined as definitely not getting vaccinated or being undecided
57 on whether to get vaccinated if a COVID-19 vaccine were available. Log-binomial models were
58 used to calculate the adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for
59 associations between potential determinants and COVID-19 vaccine hesitancy. The percentage
60 of COVID-19 vaccine hesitancy was 15% in rural Kersa, 24% in rural Ibadan, 31% in rural
61 Nouna, 33% in urban Ouagadougou, 37% in urban Addis Ababa, 48% in rural Kintampo, 64% in
62 urban Lagos, 76% in urban Dar es Salaam, and 88% in rural Dodoma. Perceived low necessity,
63 concerns about vaccine safety, and concerns about vaccine effectiveness were the leading
64 reasons for hesitancy. Healthcare workers, parents or family members, and schoolteachers had
65 the greatest impacts on vaccine willingness. Perceived lack of safety (aPR: 3.61; 95% CI: 3.10,
66 4.22) and lack of effectiveness (aPR: 3.59; 95% CI: 3.09, 4.18) were associated with greater
67 vaccine hesitancy. The levels of COVID-19 vaccine hesitancy among adolescents are alarmingly
68 high across the five sub-Saharan African countries, especially in Tanzania. COVID-19

69 vaccination campaigns among sub-Saharan African adolescents should address their concerns
70 and misconceptions about vaccine safety and effectiveness.

71

72 **Keywords:** COVID-19; vaccines; vaccine hesitancy; adolescents; sub-Saharan Africa; telephone

73 survey

74 **Introduction**

75 With unprecedented speed, multiple vaccines against SARS-CoV-2 were developed one
76 year after the beginning of the coronavirus disease 2019 (COVID-19) pandemic. While the
77 COVID-19 vaccination campaigns worldwide continue with the immunization of adults,
78 COVID-19 vaccines have been or may be made available to adolescents in many settings. The
79 United States Centers for Disease Control and Prevention currently recommends the Pfizer-
80 BioNTech COVID-19 vaccine to children and adolescents ages 5 to 17 years old [1].

81 The morbidity and mortality from COVID-19 are much lower in adolescents than among
82 adults, especially when compared to the most vulnerable group aged 65 years and older [2].
83 However, there is a strong rationale for providing COVID-19 vaccines to children and
84 adolescents. Infected adolescents can still transmit the virus to other individuals [3], and some
85 adolescents do themselves develop severe symptoms and complications from COVID-19 [4-6].
86 Therefore, vaccinating the adolescent population has the dual benefits of protecting adolescents
87 against morbidity and mortality while reducing the spread of the virus by promoting herd
88 immunity [3, 7]. In sub-Saharan Africa, adolescents aged 10 to 19 years make up 23% of the
89 population [8]. Therefore, getting COVID-19 vaccines into the arms of adolescents is crucial for
90 Africa to achieve the World Health Organization's target of 70% COVID-19 vaccination
91 coverage by mid-2022 [9]. Further, adolescents may serve as agents of advocacy that encourage
92 their family members and friends to get vaccinated [10].

93 Existing evidence shows that COVID-19 vaccines are safe and effective in adolescents
94 [11]. However, studies in high-income settings show the concerning issue of COVID-19 vaccine
95 hesitancy among adolescents. A survey conducted by the United States Centers for Disease
96 Control and Prevention among adolescents and their parents in April 2021 (just before the

97 expanded availability of the Pfizer-BioNTech vaccine to adolescents) showed that only 52% of
98 unvaccinated adolescents aged 13 to 17 years would definitely or probably receive a COVID-19
99 vaccine [12]. Vaccine hesitancy, defined as the reluctance to accept available vaccines [13], was
100 considered by the World Health Organization as one of the top threats to global health even
101 before the COVID-19 pandemic [14]. Vaccine hesitancy of adolescents poses a challenge to the
102 global effort to control the COVID-19 pandemic.

103 Perceptions and attitudes toward vaccines are heavily driven by cultural, social,
104 historical, political, and individual factors that greatly vary across cultural and geographical
105 settings [15]. As a result, COVID-19 vaccine hesitancy varies considerably across regions and
106 countries, as shown repeatedly in previous surveys among adults [16-21]. Further, the levels and
107 determinants of vaccine hesitancy in adults may not match those among adolescents [22].
108 Previous studies on COVID-19 vaccine hesitancy of adolescents were conducted in high-income
109 countries [12, 22-25] and China [10], whereas studies in sub-Saharan African countries [19, 26-
110 32] and other LMICs [31, 33-43] have primarily examined the adult population. To the best of
111 our knowledge, no study has specifically examined the levels and determinants of COVID-19
112 vaccine hesitancy among adolescents across diverse settings in sub-Saharan Africa, a region
113 where adolescents make up a considerable share of the population [44].

114 With the COVID-19 vaccination efforts around the globe moving toward children and
115 adolescents, a better understanding of the extent and the driving factors of vaccine hesitancy in
116 adolescents is needed to devise vaccination campaigns that increase vaccine uptake among
117 adolescents. In this telephone survey across five sub-Saharan African countries, we aimed to
118 assess the levels of COVID-19 vaccine hesitancy in adolescents and evaluate the potential
119 determinants of adolescent COVID-19 vaccine hesitancy.

120 **Methods**

121 **Study design and study population**

122 This cross-country study was based on an ongoing survey that used a novel mobile
123 platform and computer-assisted telephone interviewing to collect data from sub-Saharan African
124 adolescents, adults, and healthcare providers. In the previous round of the survey (Round 1), six
125 areas from three countries were included, namely Nouna and Ouagadougou in Burkina Faso,
126 Kersa and Addis Ababa in Ethiopia, and Ibadan and Lagos in Nigeria. In each country, one rural
127 area (Nouna, Kersa, and a rural subarea in Ibadan) and one urban area (Ouagadougou, Addis
128 Ababa, and Lagos) were included. The details of the study design and study population in Round
129 1 were described previously [45]. In the currently reported new round (Round 2), a rural subarea
130 in Kintampo (Ghana), a rural subarea in Dodoma (Tanzania), and an urban subarea in Dar es
131 Salaam (Tanzania) were added as new participating areas. Therefore, the Round 2 survey
132 included nine areas from five countries. Although Ibadan and Dodoma are generally considered
133 urban, the surveys were conducted in more rural subareas of Ibadan and Dodoma. The countries
134 and areas were selected based on existing collaborations and infrastructure available in the
135 African Research, Implementation Science and Education (ARISE) Network [46] to represent
136 diverse settings across sub-Saharan Africa.

137 The detailed study protocol of the Round 2 survey is available on the website of the
138 Harvard University Center for African Studies ([https://africa.harvard.edu/files/african-](https://africa.harvard.edu/files/african-studies/files/arise_covid_survey_round_2_methods_brief_final.pdf)
139 [studies/files/arise_covid_survey_round_2_methods_brief_final.pdf](https://africa.harvard.edu/files/african-studies/files/arise_covid_survey_round_2_methods_brief_final.pdf)). Briefly, during Round 2,
140 households were selected from sampling frames of existing Health and Demographic
141 Surveillance Systems (HDSSs) or national surveys, where possible. Within the sampling frame
142 in each area, we interviewed approximately 300 randomly selected households with adolescents

143 between the ages of 10 to 19 years residing in the household. The sampling frames and sampling
144 methods for Burkina Faso, Ethiopia, and Nigeria have been described in detail previously [45].
145 For the new study area of Kintampo (Ghana), we used the Kintampo HDSS as the sampling
146 frame. The Kintampo HDSS represents a catchment area of 163182 individuals and 39134
147 households. A total of 3589 adolescents were randomly sampled from the overall list of
148 households, and 1074 households were called until the target sample size of 300 adolescents was
149 reached. For the new study area of Dodoma (Tanzania), we used the Dodoma HDSS as the
150 sampling frame; 600 households with adolescents were selected randomly from the sampling
151 frame, and 318 eligible adolescents completed the survey. For the new study area of Dar es
152 Salaam (Tanzania), we used the Dar es Salaam HDSS, also referred to as the Dar es Salaam
153 Urban Cohort Study (DUCS) [47], as the sampling frame. The Dar es Salaam HDSS included
154 14754 households comprised of 143452 individuals, of which 30446 were adolescents. We
155 randomly selected 2500 households, and approximately 655 households were contacted to attain
156 the sample size of 302 adolescents.

157 The Round 1 survey was conducted between July and November 2020, and the Round 2
158 survey was conducted between July and December 2021. For the Round 2 survey, all households
159 with adolescents aged 10 to 19 years that participated in the Round 1 survey were contacted
160 again. A small number of participants aged 19 years during Round 1 and aged 20 years at the
161 time of Round 2 were also eligible for inclusion to enrich the examination of the potential
162 impacts of Round 1 predictors. For households that could not be contacted, new households were
163 randomly identified from the sampling frame until the minimum target sample size of 300
164 households per area was reached. For Tanzania and Ghana, however, none of the adolescents
165 participated in Round 1, as the two countries were added during the Round 2 survey.

166 Verbal parental consent and adolescent assent were obtained for adolescents younger
167 than 18 years of age, and oral informed consent was obtained from adolescents aged 18 years
168 and older. This study was approved by the Institutional Review Board at Harvard T.H. Chan
169 School of Public Health and ethical review boards in each country and area, including the Nouna
170 Health Research Center Ethical Committee and National Ethics Committee in Burkina Faso, the
171 Institutional Ethical Review Board of Addis Continental Institute of Public Health in Ethiopia,
172 Kintampo Health Research Centre Institutional Ethics Committee in Ghana, the University of
173 Ibadan Research Ethics Committee and National Health Research Ethics Committee in Nigeria,
174 and the University of Dodoma, Muhimbili University of Health and Allied Sciences, and
175 National Institute for Medical Research in Tanzania.

176

177 **Data collection**

178 The Round 1 survey included questions on the adolescents' sociodemographic
179 characteristics, knowledge and perceptions of COVID-19, and the impacts of the COVID-19
180 pandemic on adolescents' education, daily activities, communication, media consumption, and
181 various health domains, including dietary intake and mental health [48]. The Round 2 survey
182 focused heavily on adolescents' awareness, knowledge, perceptions, and attitudes toward
183 COVID-19 vaccines, willingness to receive COVID-19 vaccines, potential determinants of
184 COVID-19 vaccine hesitancy, trusted sources of information regarding COVID-19 vaccines, and
185 the expectations on COVID-19 vaccine campaigns. The complete adolescent instrument used for
186 the Round 2 survey is available on the website of the Harvard University Center for African
187 Studies ([https://africa.harvard.edu/files/african-studies/files/arise_covid-](https://africa.harvard.edu/files/african-studies/files/arise_covid-19_survey_round_2_adolescent_household_survey_questionnaire.pdf)
188 [19_survey_round_2_adolescent_household_survey_questionnaire.pdf](https://africa.harvard.edu/files/african-studies/files/arise_covid-19_survey_round_2_adolescent_household_survey_questionnaire.pdf)).

189

190 **Statistical analysis**

191 We conducted descriptive analyses on the sociodemographic characteristics of the
192 adolescents, willingness to receive the COVID-19 vaccine, perceptions of the vaccine, self-
193 reported determinants of their willingness to be vaccinated, and their trusted information sources
194 and expectations about the vaccine. For the descriptive analyses, we calculated means and
195 standard deviations (SDs) overall and by area for continuous variables and counts and
196 percentages for categorical variables.

197 The outcome for the associational analyses was COVID-19 vaccine hesitancy, defined as
198 a response of definitely not getting the COVID-19 vaccine or maybe, unsure, or undecided on
199 whether to get the COVID-19 vaccine if it were available now. We defined vaccine hesitancy as
200 a dichotomous outcome. The potential determinants included age, sex, country, rural residence,
201 currently receiving education, perceived safety of the COVID-19 vaccine among children and
202 adolescents, perceived effectiveness of the COVID-19 vaccine, current impacts of the COVID-
203 19 pandemic on daily activities, levels of psychological distress measured using the four-item
204 Patient Health Questionnaire for Depression and Anxiety Scale [49], perceived risk of being
205 exposed to COVID-19 during Round 1 (for Round 1 participants only), and knowledge score on
206 the symptoms, transmission, and prevention of COVID-19 measured during Round 1 (for Round
207 1 participants only).

208 We used log-binomial models to calculate the prevalence ratios (PRs) and 95%
209 confidence intervals (CIs) and modified Poisson models to achieve model convergence whenever
210 necessary [50]. We examined the crude associations between potential determinants and vaccine
211 hesitancy in unadjusted models. We estimated adjusted prevalence ratios (aPRs) in adjusted

212 models controlled for age, sex, country, and rural residence. We conducted all analyses using
213 SAS 9.4 (SAS Institute Inc., Cary, North Carolina) at a two-sided α level of 0.05. Missing data
214 were handled using the complete case analysis.
215

216 Results

217 Sociodemographic characteristics

218 A total of 2803 adolescents were interviewed (**Table 1**). The age of the adolescents ranged from a minimum of 10 years to a
 219 maximum of 20 years. The mean age ranged from 14 years in Dodoma (SD: 2.3) and Dar es Salaam (SD: 2.6) to 17 years in Addis
 220 Ababa (SD: 2.4) and Ibadan (SD: 2.0). The sex distributions were roughly balanced between girls and boys, except for Kersa, where
 221 31% were girls, and Addis Ababa, where 62% were girls. The percentage of adolescents with at least some secondary school
 222 education ranged from 16% in Dodoma to 96% in Ibadan. No less than 85% of the participants self-identified as students, except in
 223 Nouna and Dodoma, where 52% and 57% of the adolescents were students, respectively. In Burkina Faso, Ethiopia, and Nigeria,
 224 adolescents who also participated in the Round 1 survey varied from 9% in Lagos to 64% in Addis Ababa.

225

226 **Table 1** Sociodemographic characteristics of adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burkina Faso		Ethiopia		Ghana	Nigeria		Tanzania		Total
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	
	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, <i>N</i>	309	300	300	308	300	319	347	318	302	2803
Adolescents who also participated in Round 1 survey, <i>N</i> (%)	185 (59.9)	181 (60.3)	109 (36.3)	198 (64.3)	0 (0.0)	120 (37.6)	31 (8.9)	0 (0.0)	0 (0.0)	824 (29.4)
Age, years (SD)	15.8 (2.5)	15.8 (2.5)	16.1 (2.8)	17.0 (2.4)	15.6 (2.7)	16.9 (2.0)	16.0 (1.9)	14.4 (2.3)	14.1 (2.6)	15.7 (2.6)
Girls, <i>N</i> (%)	140 (45.3)	161 (53.7)	92 (30.7)	191 (62.0)	153 (51.0)	175 (54.9)	206 (59.4)	175 (55.0)	177 (58.6)	1470 (52.4)
Highest level of education, ^{2,3} <i>N</i> (%)										
None/religious school/literacy class	38 (12.4)	17 (5.7)	2 (0.7)	1 (0.3)	10 (3.3)	1 (0.3)	0 (0.0)	34 (10.7)	0 (0.0)	103 (3.7)
Some primary school	90 (29.4)	58 (19.3)	139 (46.3)	59 (19.2)	109 (36.3)	3 (0.9)	0 (0.0)	169 (53.1)	109 (36.5)	736 (26.3)
Completed primary school	40 (13.1)	16 (5.3)	30 (10.0)	30 (9.7)	46 (15.3)	9 (2.8)	17 (4.9)	65 (20.4)	52 (17.4)	305 (10.9)
Some secondary/high school	114 (37.3)	186 (62.0)	103 (34.3)	130 (42.2)	127 (42.3)	216 (67.9)	299 (86.2)	48 (15.1)	113 (37.8)	1336 (47.8)
Completed secondary/high school	11 (3.6)	20 (6.7)	10 (3.3)	50 (16.2)	7 (2.3)	78 (24.5)	27 (7.8)	2 (0.6)	19 (6.4)	224 (8.0)

Tertiary education or higher	13 (4.3)	3 (1.0)	16 (5.3)	38 (12.3)	1 (0.3)	11 (3.5)	4 (1.2)	0 (0.0)	6 (2.0)	92 (3.3)
Occupation ⁴ N (%)										
Unemployed	21 (6.8)	12 (4.0)	2 (0.7)	5 (1.6)	11 (3.7)	0 (0.0)	0 (0.0)	71 (22.3)	21 (7.0)	143 (5.1)
Student	161 (52.1)	255 (85.0)	278 (92.7)	290 (94.2)	259 (86.3)	309 (97.5)	342 (98.6)	181 (56.9)	267 (88.4)	2342 (83.6)
Farmer	86 (27.8)	0 (0.0)	16 (5.3)	2 (0.7)	14 (4.7)	0 (0.0)	0 (0.0)	34 (10.7)	1 (0.3)	153 (5.5)
Wage employment	0 (0.0)	2 (0.7)	0 (0.0)	5 (1.6)	3 (1.0)	1 (0.3)	3 (0.9)	0 (0.0)	3 (1.0)	17 (0.6)
Self-employed	7 (2.3)	9 (3.0)	2 (0.7)	6 (2.0)	8 (2.7)	6 (1.9)	2 (0.6)	1 (0.3)	10 (3.3)	51 (1.8)
Casual, off-farm income	6 (1.9)	4 (1.3)	0 (0.0)	0 (0.0)	1 (0.3)	1 (0.3)	0 (0.0)	31 (9.8)	0 (0.0)	43 (1.5)

227 ¹ Values are mean (standard deviation) for age and count (percentage) for other variables. SD, standard deviation.

228 ² Percentages may not add up to 100% due to rounding.

229 ³ Level of education missing for 3 adolescents in Nouna, 1 adolescent in Ibadan, and 3 adolescents in Dar es Salaam.

230 ⁴ Occupation missing for 2 adolescents in Ibadan.

231

232 Willingness to receive COVID-19 vaccines

233 Over 80% of adolescents had previously heard of COVID-19 vaccines, except in Nouna and Kersa, where 74% and 57% of the
234 adolescents had heard of the vaccines, respectively (**Table 2**). Kersa had the highest percentage of adolescents who would definitely
235 get vaccinated if a COVID-19 vaccine were available (86%), whereas Dodoma had the lowest percentage of willingness to definitely
236 get vaccinated (12%). Correspondingly, Dodoma had the highest percentage of adolescents who would definitely *not* get vaccinated
237 (79%), and Kersa had the lowest percentage (11%). Nouna had the highest percentage of adolescents who were unsure or undecided
238 on whether they would be vaccinated if a COVID-19 vaccine were available (17%). In ascending order, the percentage of adolescents
239 with COVID-19 vaccine hesitancy, defined as definitely not getting vaccinated or unsure/undecided, was 15% in Kersa, 24% in
240 Ibadan, 31% in Nouna, 33% in Ouagadougou, 37% in Addis Ababa, 48% in Kintampo, 64% in Lagos, 76% in Dar es Salaam, and
241 88% in Dodoma. Among adolescents who were definitely or possibly willing to receive COVID-19 vaccines, keeping themselves and
242 their families safe was the most common reason for vaccination, cited by over 92% of adolescents in all areas except in Dodoma

243 (63%) and Dar es Salaam (89%). Parental or familial will was the second common driver for vaccination, selected by over 60% of
 244 adolescents in all areas except Addis Ababa (45%) and Dodoma (25%). Doctors' suggestions were the third common motivation for
 245 vaccination, chosen by over 40% of adolescents in all areas except Dodoma (16%) and Dar es Salaam (35%). Among adolescents who
 246 were definitely not or possibly not willing to receive COVID-19 vaccines, the leading reasons for hesitancy were perceived low
 247 necessity (selected by 47% of adolescents overall), concerns about the safety of the vaccine (selected by 46% overall), and concerns
 248 about the effectiveness of the vaccine (selected by 12% overall). Personal liberty concerns, the influence of conspiracy theories,
 249 religious reasons, and fears of getting unlicensed, experimental, or worse-quality vaccines were not the main reasons for hesitancy,
 250 each cited by less than 3% of adolescents.

251

252 **Table 2** Willingness to receive the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burkina Faso		Ethiopia		Ghana	Nigeria		Tanzania		Total
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	
	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, <i>N</i>	309	300	300	308	300	319	347	318	302	2803
Having heard of COVID-19 vaccine, ² <i>N</i> (%)	225 (73.5)	270 (90.0)	165 (56.9)	303 (98.4)	261 (87.9)	280 (90.0)	337 (97.1)	267 (84.0)	295 (98.0)	2403 (86.5)
Willingness to receive COVID-19 vaccine if it were available now, ^{3,4} <i>N</i> (%)										
Would definitely not get vaccinated	30 (13.3)	71 (26.4)	18 (10.9)	89 (29.4)	92 (35.3)	45 (16.1)	176 (52.2)	210 (78.7)	198 (67.1)	929 (38.7)
Would definitely get vaccinated	156 (69.3)	179 (66.5)	141 (85.5)	191 (63.0)	136 (52.1)	212 (76.0)	123 (36.5)	32 (12.0)	72 (24.4)	1242 (51.7)
Maybe/unsure/undecided	39 (17.3)	19 (7.1)	6 (3.6)	23 (7.6)	33 (12.6)	22 (7.9)	38 (11.3)	25 (9.4)	25 (8.5)	230 (9.6)
Reasons for getting the COVID-19 vaccine, ^{5,6} <i>N</i> (%)										
To keep self and family safe	182 (93.3)	195 (98.5)	143 (97.3)	212 (99.1)	156 (92.3)	225 (96.2)	155 (96.3)	36 (63.2)	86 (88.7)	1390 (94.4)
Parents' or family's will	172 (88.2)	174 (87.9)	106 (72.1)	96 (44.9)	125 (74.0)	189 (80.8)	98 (60.9)	14 (24.6)	69 (71.1)	1043 (70.9)
Because doctor suggested	156 (80.0)	192 (97.0)	66 (44.9)	96 (44.9)	119 (70.4)	172 (73.5)	76 (47.2)	9 (15.8)	34 (35.1)	920 (62.5)
Reasons for not getting the COVID-19 vaccine, ^{5,7} <i>N</i> (%)										
Perceived low necessity of being vaccinated	48 (71.6)	52 (60.5)	15 (62.5)	37 (33.3)	20 (18.0)	22 (36.1)	81 (38.2)	168 (90.8)	59 (26.8)	502 (46.6)
Concerns about effectiveness of the vaccine	9 (13.4)	28 (32.6)	0 (0.0)	23 (20.7)	7 (6.3)	7 (11.5)	40 (18.9)	2 (1.1)	8 (3.6)	124 (11.5)
Concerns about safety of the vaccine	24 (35.8)	55 (64.0)	9 (37.5)	74 (66.7)	59 (53.2)	33 (54.1)	146 (68.9)	6 (3.2)	88 (40.0)	494 (45.9)

Fear of getting unlicensed/experimental/worse-quality vaccines	2 (3.0)	1 (1.2)	0 (0.0)	4 (3.6)	3 (2.7)	1 (1.6)	11 (5.2)	1 (0.5)	2 (0.9)	25 (2.3)
Religious reasons	0 (0.0)	0 (0.0)	0 (0.0)	12 (10.8)	1 (0.9)	0 (0.0)	2 (0.9)	0 (0.0)	1 (0.5)	16 (1.5)
Influence of conspiracy theories	1 (1.5)	1 (1.2)	0 (0.0)	5 (4.5)	13 (11.7)	2 (3.3)	4 (1.9)	0 (0.0)	0 (0.0)	26 (2.4)
Personal liberty concerns	0 (0.0)	2 (2.3)	0 (0.0)	2 (1.8)	5 (4.5)	0 (0.0)	1 (0.5)	2 (1.1)	3 (1.4)	15 (1.4)

253 ¹ Values are counts (percentages) for categorical variables.

254 ² Missing for 3 adolescents in Nouna, 10 adolescents in Kersa, 8 adolescents in Ibadan, 1 adolescent in Dar es Salaam, and 3 adolescents in Kintampo.

255 ³ Percentages may not add up to 100% due to rounding.

256 ⁴ Among adolescents who have heard of COVID-19 vaccines. Missing for 1 adolescent in Ouagadougou and 1 adolescent in Ibadan.

257 ⁵ Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

258 ⁶ Counts and percentages are among adolescents who would definitely get vaccinated and who were unsure/undecided.

259 ⁷ Counts and percentages are among adolescents who would definitely not get vaccinated and who were unsure/undecided. Missing for 2 adolescents in Nouna, 4 adolescents in

260 Ouagadougou, 1 adolescent in Addis Ababa, 6 adolescents in Ibadan, 2 adolescents in Lagos, 3 adolescents in Dar es Salaam, 50 adolescents in Dodoma, and 14 adolescents in

261 Kintampo.

262

263 Perceptions of COVID-19 vaccines

264 The percentage of adolescents who perceived COVID-19 vaccines to be very safe or somewhat safe among the general

265 population ranged from 38% in Dodoma to 76% in Kersa and Addis Ababa (**Table 3**). Similarly, the percentage of adolescents

266 perceiving COVID-19 vaccines as very safe or somewhat safe among children and adolescents varied from 33% in Dodoma to 77% in

267 Kersa. In terms of the perceived effectiveness of COVID-19 vaccines among the general population, 39% of participants in Dodoma

268 to 80% of participants in Kersa perceived COVID-19 vaccines to be very effective or somewhat effective in preventing COVID-19

269 infection. Overall, 46% of adolescents could not identify any possible side effects of COVID-19 vaccines, and 27% believed that there

270 were no side effects from the vaccines.

271

272 **Table 3** Perceptions of the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burkina Faso		Ethiopia		Ghana	Nigeria		Tanzania		Total
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	

	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, <i>N</i>	309	300	300	308	300	319	347	318	302	2803
Perceived safety of the COVID-19 vaccine in general, ^{2,3} <i>N</i> (%)										
Very safe	135 (43.7)	119 (39.9)	224 (74.7)	50 (16.2)	67 (22.3)	171 (53.6)	97 (28.0)	46 (14.5)	92 (30.5)	1001 (35.7)
Somewhat safe	68 (22.0)	56 (18.8)	4 (1.3)	184 (59.7)	69 (23.0)	61 (19.1)	90 (25.9)	76 (23.9)	57 (18.9)	665 (23.7)
Not very safe	50 (16.2)	54 (18.1)	6 (2.0)	28 (9.1)	42 (14.0)	24 (7.5)	83 (23.9)	80 (25.2)	28 (9.3)	395 (14.1)
Not safe at all	5 (1.6)	20 (6.7)	2 (0.7)	25 (8.1)	16 (5.3)	12 (3.8)	28 (8.1)	19 (6.0)	54 (17.9)	181 (6.5)
Do not know	51 (16.5)	49 (16.4)	64 (21.3)	21 (6.8)	106 (35.3)	51 (16.0)	49 (14.1)	97 (30.5)	71 (23.5)	559 (20.0)
Perceived safety of the COVID-19 vaccine among children and adolescents, ^{2,4} <i>N</i> (%)										
Very safe	131 (42.4)	91 (31.4)	230 (76.7)	67 (21.8)	50 (16.7)	151 (47.3)	93 (26.8)	39 (12.3)	84 (27.8)	936 (33.5)
Somewhat safe	65 (21.0)	62 (21.4)	2 (0.7)	141 (45.8)	59 (19.7)	67 (21.0)	85 (24.5)	66 (20.8)	47 (15.6)	594 (21.3)
Not very safe	53 (17.2)	58 (20.0)	7 (2.3)	42 (13.6)	48 (16.0)	31 (9.7)	84 (24.2)	84 (26.5)	28 (9.3)	435 (15.6)
Not safe at all	7 (2.3)	25 (8.6)	2 (0.7)	30 (9.7)	27 (9.0)	11 (3.5)	30 (8.7)	31 (9.8)	66 (21.9)	229 (8.2)
Do not know	53 (17.2)	54 (18.6)	59 (19.7)	28 (9.1)	116 (38.7)	59 (18.5)	55 (15.9)	97 (30.6)	77 (25.5)	598 (21.4)
Perceived effectiveness of the COVID-19 vaccine in general, ^{2,5} <i>N</i> (%)										
Very effective	136 (44.0)	120 (40.8)	220 (73.3)	66 (21.4)	63 (21.0)	164 (51.4)	88 (25.4)	48 (15.2)	71 (23.5)	976 (34.9)
Somewhat effective	65 (21.0)	56 (19.1)	20 (6.7)	149 (48.4)	58 (19.3)	72 (22.6)	81 (23.3)	75 (23.8)	57 (18.9)	633 (22.7)
Not very effective	42 (13.6)	38 (12.9)	5 (1.7)	30 (9.7)	31 (10.3)	24 (7.5)	71 (20.5)	80 (25.4)	31 (10.3)	352 (12.6)
Not effective at all	6 (1.9)	20 (6.8)	2 (0.7)	21 (6.8)	16 (5.3)	5 (1.6)	25 (7.2)	19 (6.0)	54 (17.9)	168 (6.0)
Do not know	60 (19.4)	60 (20.4)	53 (17.7)	42 (13.6)	132 (44.0)	54 (16.9)	82 (23.6)	93 (29.5)	89 (29.5)	665 (23.8)
Perceived side effects of the COVID-19 vaccine, ^{6,7} <i>N</i> (%)										
No side effects	52 (16.8)	73 (24.4)	130 (43.3)	105 (34.1)	49 (16.3)	111 (34.8)	54 (15.6)	99 (31.3)	88 (29.1)	761 (27.2)
Fever	64 (20.7)	42 (14.1)	1 (0.3)	69 (22.4)	33 (11.0)	58 (18.2)	83 (23.9)	3 (1.0)	25 (8.3)	378 (13.5)
Body ache including sore arm	59 (19.1)	19 (6.4)	7 (2.3)	115 (37.3)	38 (12.7)	74 (23.2)	94 (27.1)	3 (1.0)	13 (4.3)	422 (15.1)
Nausea	54 (17.5)	22 (7.4)	1 (0.3)	51 (16.6)	10 (3.3)	11 (3.5)	19 (5.5)	0 (0.0)	6 (2.0)	174 (6.2)
Tiredness/exhaustion	62 (20.1)	38 (12.7)	7 (2.3)	76 (24.7)	24 (8.0)	73 (22.9)	69 (19.9)	0 (0.0)	10 (3.3)	359 (12.8)
Do not know any	183 (59.2)	158 (52.8)	158 (52.7)	41 (13.3)	179 (59.7)	109 (34.2)	124 (35.7)	203 (64.2)	119 (39.4)	1274 (45.5)

273 ¹ Values are counts (percentages) for categorical variables.

274 ² Percentages may not add up to 100% due to rounding.

275 ³ Missing for 2 adolescents in Ouagadougou.

276 ⁴ Missing for 10 adolescents in Ouagadougou and 1 adolescent in Dodoma.

277 ⁵ Missing for 6 adolescents in Ouagadougou and 3 adolescents in Dodoma.

278 ⁶ Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

279 ⁷ Missing for 1 adolescent in Ouagadougou and 2 adolescents in Dodoma.

280

281 Self-reported determinants of willingness to receive vaccines

282 The percentage of adolescents whose willingness to receive COVID-19 vaccines would be affected by the vaccine's country of
 283 origin ranged from 15% in Ibadan to 44% in Lagos (**Table 4**). In descending order, the overall percentages of adolescents willing to
 284 receive COVID-19 vaccines developed by specific countries were 37% for the United States, 21% for China, 15% for Europe, 13%
 285 for Russia, and 11% for India. Overall, 29% of the participants would be more willing to receive a COVID-19 vaccine developed or
 286 tested in Africa, ranging from 15% in Ibadan to 48% in Kintampo. The individuals or groups that had the greatest impacts on the
 287 adolescents' willingness to receive COVID-19 vaccines were healthcare workers (60% overall), parents or family members (58%
 288 overall), and schoolteachers (46% overall). Religious leaders affected COVID-19 vaccine willingness for over 20% of adolescents in
 289 all areas (36% overall).

290

291 **Table 4** Determinants of the willingness to receive the COVID-19 vaccine among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	Burkina Faso		Ethiopia		Ghana	Nigeria		Tanzania		Total
	Rural	Urban	Rural	Urban	Rural	Rural	Urban	Rural	Urban	
	Nouna	Ouagadougou	Kersa	Addis Ababa	Kintampo	Ibadan	Lagos	Dodoma	Dar es Salaam	
Number of adolescents, <i>N</i>	309	300	300	308	300	319	347	318	302	2803
Willingness affected by the vaccine's country of origin, ^{2,3} <i>N</i> (%)										
No	224 (72.5)	170 (56.7)	197 (65.7)	217 (70.5)	183 (61.4)	253 (79.3)	179 (51.7)	210 (68.2)	209 (69.2)	1842 (66.0)
Yes	75 (24.3)	118 (39.3)	58 (19.3)	86 (27.9)	88 (29.5)	48 (15.1)	152 (43.9)	49 (15.9)	66 (21.9)	740 (26.5)
Do not know	10 (3.2)	12 (4.0)	45 (15.0)	5 (1.6)	27 (9.1)	18 (5.6)	15 (4.3)	49 (15.9)	27 (8.9)	208 (7.5)
Willing to receive COVID-19 vaccine developed by the country, ^{4,5} <i>N</i> (%)										
United States	36 (42.4)	41 (31.5)	19 (18.5)	33 (36.3)	53 (46.9)	35 (53.0)	112 (67.1)	1 (1.1)	14 (15.1)	344 (36.6)
China	33 (38.8)	48 (36.9)	27 (26.2)	24 (26.4)	22 (19.5)	5 (7.6)	28 (16.8)	1 (1.1)	9 (9.7)	197 (21.0)
Russia	26 (30.6)	27 (20.8)	6 (5.8)	12 (13.2)	39 (34.5)	4 (6.1)	10 (6.0)	0 (0.0)	1 (1.1)	125 (13.3)
India	15 (17.7)	26 (20.0)	3 (2.9)	6 (6.6)	29 (25.7)	4 (6.1)	18 (10.8)	1 (1.1)	2 (2.2)	104 (11.1)
Europe	18 (21.2)	18 (13.9)	9 (8.7)	12 (13.2)	29 (25.7)	14 (21.2)	33 (19.8)	0 (0.0)	3 (3.2)	136 (14.5)
Do not know	24 (28.2)	12 (9.2)	45 (43.7)	19 (20.9)	28 (24.8)	18 (27.3)	28 (16.8)	56 (61.5)	34 (36.6)	264 (28.1)
Willingness of receiving a COVID-19 vaccine developed or tested in Africa, ^{2,6} <i>N</i> (%)										
Would not affect willingness	167 (54.2)	123 (41.0)	187 (62.3)	194 (63.0)	122 (40.7)	227 (71.2)	187 (53.9)	196 (65.3)	179 (59.3)	1582 (56.8)

Would decrease willingness	13 (4.2)	24 (8.0)	3 (1.0)	48 (15.6)	15 (5.0)	27 (8.5)	62 (17.9)	6 (2.0)	0 (0.0)	198 (7.1)
Would increase willingness	111 (36.0)	138 (46.0)	70 (23.3)	58 (18.8)	143 (47.7)	49 (15.4)	86 (24.8)	55 (18.3)	103 (34.1)	813 (29.2)
Do not know	17 (5.5)	15 (5.0)	40 (13.3)	8 (2.6)	20 (6.7)	16 (5.0)	12 (3.5)	43 (14.3)	20 (6.6)	191 (6.9)
Willingness affected by individuals or groups, ⁴ <i>N</i> (%)										
Parents or family members	248 (80.3)	218 (72.7)	158 (52.7)	110 (35.7)	231 (77.0)	233 (73.0)	252 (72.6)	42 (13.2)	130 (43.1)	1622 (57.9)
Religious leaders	143 (46.3)	119 (39.7)	102 (34.0)	90 (29.2)	161 (53.7)	104 (32.6)	150 (43.2)	68 (21.4)	74 (24.5)	1011 (36.1)
Community/tribal leaders	113 (36.6)	104 (34.7)	83 (27.7)	89 (28.9)	141 (47.0)	61 (19.1)	66 (19.0)	21 (6.6)	19 (6.3)	697 (24.9)
Political leaders	63 (20.4)	131 (43.7)	75 (25.0)	49 (15.9)	115 (38.3)	49 (15.4)	56 (16.1)	27 (8.5)	47 (15.6)	612 (21.8)
Celebrities or social media influencers	38 (12.3)	68 (22.7)	21 (7.0)	61 (19.8)	83 (27.7)	51 (16.0)	64 (18.4)	12 (3.8)	30 (9.9)	428 (15.3)
Healthcare workers	211 (68.3)	226 (75.3)	158 (52.7)	172 (55.8)	222 (74.0)	238 (74.6)	244 (70.3)	136 (42.8)	81 (26.8)	1688 (60.2)
Schoolteachers	168 (54.4)	167 (55.7)	152 (50.7)	89 (28.9)	164 (54.7)	163 (51.1)	101 (29.1)	110 (34.6)	164 (54.3)	1278 (45.6)

292 ¹ Values are counts (percentages) for categorical variables.

293 ² Percentages may not add up to 100% due to rounding.

294 ³ Missing for 1 adolescent in Lagos, 10 adolescents in Dodoma, and 2 adolescents in Kintampo.

295 ⁴ Counts and percentages do not add up to the total because the selection of multiple reasons was allowed.

296 ⁵ Counts and percentages are among adolescents whose willingness to take a COVID-19 vaccine may be affected by the vaccine's country of origin. Missing for 7 adolescents in
297 Dodoma and 2 adolescents in Kintampo.

298 ⁶ Missing for 1 adolescent in Nouna and 18 adolescents in Dodoma.

299

300 **Trusted information sources and expectations of vaccines**

301 The most highly trusted sources of information on COVID-19 vaccines for adolescents were television, radio, or newspaper
302 (85% overall), medical professionals (83% overall), and governmental communications (74% overall) (**S1 Table**). The adolescents'
303 willingness to participate in a COVID-19 vaccine trial ranged from 14% in Dodoma to 65% in Kersa. No more than 2% of the
304 adolescents had already received a COVID-19 vaccine, except in Ibadan, where 13% had been vaccinated. Overall, 41% of the
305 adolescents did not know when a COVID-19 vaccine would be made available to them. In particular, 70% of adolescents in Dodoma
306 and 41% in Dar es Salaam thought that a COVID-19 vaccine would never be made available to them. Overall, 90% of adolescents
307 believed that individuals should continue following COVID-19 preventative guidelines even after vaccines became available.

308

309 **Potential determinants of COVID-19 vaccine hesitancy**

310 Older age was associated with a lower prevalence of COVID-19 vaccine hesitancy (aPR: 0.98; 95% CI: 0.97, 1.00) (**Table 5**).
311 Compared to girls, boys were 8% less likely to have vaccine hesitancy (aPR: 0.92; 95% CI: 0.86, 0.98). Compared to adolescents in
312 Burkina Faso, adolescents in Ethiopia were similarly likely to have COVID-19 vaccine hesitancy (aPR: 0.91; 95% CI: 0.75, 1.11),
313 adolescents in Ghana were 55% more likely to have COVID-19 vaccine hesitancy (aPR: 1.55; 95% CI: 1.28, 1.86), adolescents in
314 Nigeria were 44% more likely to have COVID-19 vaccine hesitancy (aPR: 1.44; 95% CI: 1.23, 1.68), and adolescents in Tanzania
315 were 142% more likely to have COVID-19 vaccine hesitancy (aPR: 2.42; 95% CI: 2.11, 2.78). Rural residence was associated with an
316 8% lower prevalence of vaccine hesitancy (aPR: 0.92; 95% CI: 0.85, 1.00). Compared to those who perceived COVID-19 vaccines to
317 be very safe among children and adolescents, adolescents perceiving COVID-19 vaccines to be somewhat safe, not very safe, and not
318 safe at all had 1.8 times (aPR: 1.83; 95% CI: 1.54, 2.16), 3.5 times (aPR: 3.50; 95% CI: 3.01, 4.06), and 3.6 times (aPR: 3.61; 95% CI:
319 3.10, 4.22) the prevalence of COVID-19 vaccine hesitancy, respectively. Similarly, compared to adolescents who believed that
320 COVID-19 vaccines were very effective, adolescents who perceived COVID-19 vaccines to be somewhat effective, not very effective,
321 and not effective at all had 1.9 times (aPR: 1.94; 95% CI: 1.66, 2.28), 3.4 times (aPR: 3.37; 95% CI: 2.91, 3.90), and 3.6 times (aPR:
322 3.59; 95% CI: 3.09, 4.18) the prevalence of vaccine hesitancy, respectively. Experiencing any current impacts of the COVID-19
323 pandemic on daily activities was associated with an 11% lower prevalence of COVID-19 vaccine hesitancy (aPR: 0.89; 95% CI: 0.81,
324 0.97). Currently receiving education, levels of psychological distress, perceived risk of exposure to COVID-19 during Round 1, and
325 level of COVID-19 knowledge during Round 1 were not significantly associated with COVID-19 vaccine hesitancy.

327 **Table 5** Potential determinants of COVID-19 vaccine hesitancy among adolescents in a phone-based survey in five sub-Saharan African countries, 2021¹

	COVID-19 vaccine hesitancy ²	
	Unadjusted	Adjusted
	PR (95% CI)	aPR (95% CI)
Age, years	0.95 (0.93, 0.96)	0.98 (0.97, 1.00)
Male sex	0.84 (0.78, 0.92)	0.92 (0.86, 0.98)
Country		
Burkina Faso	1.00 (Ref)	1.00 (Ref)
Ethiopia	0.90 (0.75, 1.09)	0.91 (0.75, 1.11)
Ghana	1.49 (1.24, 1.78)	1.55 (1.28, 1.86)
Nigeria	1.42 (1.21, 1.65)	1.44 (1.23, 1.68)
Tanzania	2.53 (2.21, 2.89)	2.42 (2.11, 2.78)
Rural residence	0.82 (0.75, 0.89)	0.92 (0.85, 1.00)
Not currently receiving education	0.81 (0.70, 0.93)	1.04 (0.92, 1.19)
Perceived safety of the COVID-19 vaccine among children and adolescents		
Very safe	1.00 (Ref)	1.00 (Ref)
Somewhat safe	1.93 (1.61, 2.30)	1.83 (1.54, 2.16)
Not very safe	3.89 (3.34, 4.53)	3.50 (3.01, 4.06)
Not safe at all	4.64 (4.01, 5.38)	3.61 (3.10, 4.22)
Do not know	3.33 (2.85, 3.89)	2.82 (2.42, 3.30)
Perceived effectiveness of the COVID-19 vaccine		
Very effective	1.00 (Ref)	1.00 (Ref)
Somewhat effective	2.09 (1.77, 2.46)	1.94 (1.66, 2.28)
Not very effective	3.93 (3.39, 4.55)	3.37 (2.91, 3.90)
Not effective at all	4.69 (4.08, 5.40)	3.59 (3.09, 4.18)
Do not know	3.33 (2.87, 3.87)	2.82 (2.43, 3.28)
Current impacts of the COVID-19 pandemic on daily activities		
No impacts	1.00 (Ref)	1.00 (Ref)
Some impacts	1.17 (1.07, 1.28)	0.89 (0.81, 0.97)
Psychological distress ³		
No psychological distress	1.00 (Ref)	1.00 (Ref)
Mild psychological distress	0.96 (0.85, 1.09)	1.03 (0.93, 1.14)
Moderate psychological distress	0.93 (0.74, 1.16)	0.99 (0.82, 1.20)
Severe psychological distress	0.80 (0.45, 1.42)	0.89 (0.55, 1.43)
Perceived risk of exposure to COVID-19 during Round 1 ⁴		
No risk	1.00 (Ref)	1.00 (Ref)
Low risk	0.92 (0.68, 1.25)	0.87 (0.64, 1.18)
High risk	0.78 (0.55, 1.11)	0.84 (0.58, 1.21)
Very high risk	0.72 (0.41, 1.28)	0.70 (0.40, 1.24)
High knowledge score of COVID-19 during Round 1 ⁵	1.01 (0.80, 1.27)	0.90 (0.72, 1.14)

328 ¹ Values are prevalence ratios (95% confidence intervals) from log-binomial or modified Poisson models. The adjusted analyses controlled for age, sex, country, and rural
329 residence. PR, prevalence ratio; CI, confidence interval; aPR, adjusted prevalence ratio.
330 ² COVID-19 vaccine hesitancy was defined as a response of definitely not getting the COVID-19 vaccine, or a response of maybe, unsure, or undecided on whether to get the
331 COVID-19 vaccine if it were available now.
332 ³ Psychological distress was measured using the four-item Patient Health Questionnaire for Depression and Anxiety Scale. Each item had a numeric score of 0, 1, 2, and 3, and the
333 total score was computed by adding up the four items, resulting in a total score ranging from 0 to 12. The total score of psychological distress was categorized into none (total
334 score: 0 to 2), mild (total score: 3 to 5), moderate (total score: 6 to 8), and severe (total score: 9 to 12).
335 ⁴ For adolescents in Burkina Faso, Ethiopia, and Nigeria who participated in the Round 1 survey.
336 ⁵ For adolescents in Burkina Faso, Ethiopia, and Nigeria who participated in the Round 1 survey. For each of the three domains of COVID-19 knowledge (symptoms, transmission,
337 and prevention), a score was created based on the number of correct responses. The maximum scores for symptoms, transmission, and prevention were 10, 5, and 7, respectively.
338 The three scores were then added to construct a total knowledge score of COVID-19 with a range from 0 to 22. A high knowledge score was defined as a total score of 18 or
339 greater.
340

341

342 **Discussion**

343 This multi-country survey finds high COVID-19 vaccine hesitancy among adolescents
344 from the nine areas across five countries in sub-Saharan Africa. The level of hesitancy is
345 exceptionally high in Tanzania. Individual characteristics that potentially increase vaccine
346 hesitancy are female sex, perceived lack of safety, and perceived lack of effectiveness of
347 COVID-19 vaccines.

348 COVID-19 vaccine perceptions and hesitancy are influenced by social and cultural
349 factors that vary considerably across settings [15-21]. Of note, a large sample of 13,426
350 participants from the general population in 19 countries showed high heterogeneity across
351 countries in the determinants, and even the directions of associations, of vaccine acceptance [16].
352 This survey is, to our knowledge, the first study that examined the levels and determinants of
353 COVID-19 vaccine hesitancy among adolescents across various settings in sub-Saharan Africa.
354 While the proportion of adolescents with COVID-19 vaccine hesitancy is high across areas,
355 considerable variation is also noted, ranging from 15% in Kersa to 88% in Dodoma. Previous
356 studies in high- or upper-middle-income settings report similarly heterogeneous levels of
357 hesitancy. A study in adolescents aged 12 to 15 years in Arkansas, United States, reported that
358 58% were hesitant about getting a COVID-19 vaccine [22]. A study among Canadian
359 adolescents aged 14 to 17 years reported that 35% would not get a COVID-19 vaccine or were
360 unsure [24]. Based on a survey conducted by the United States Centers for Disease Control and
361 Prevention in April 2021, only 52% of unvaccinated adolescents aged 13 to 17 years would
362 definitely or probably receive COVID-19 vaccination [12]. A study among Swedish adolescents
363 showed that nearly one in three adolescents had not decided if they wanted to get a COVID-19
364 vaccine and that only 54% were willing to be vaccinated [25]. In a survey among Chinese

365 adolescents, 76% of the participants would accept future COVID-19 vaccination [10]. In our
366 survey, the exceptionally high level of vaccine hesitancy in Dodoma and Dar es Salaam is
367 perhaps attributable to the misconceptions regarding COVID-19 and its vaccination, partially
368 exacerbated by misinformation among communities in 2020 and early 2021 [51, 52].

369 We find that healthcare providers are adolescents' most trusted individuals for
370 information on COVID-19 vaccines and may have the greatest impact on the adolescents'
371 willingness to vaccinate. Even in Tanzania, where vaccine hesitancy is high, over 60% of
372 adolescents trust vaccine information from healthcare providers. Previous global surveys among
373 the general population also consistently showed that health workers are the most trusted sources
374 of guidance about COVID-19 vaccines [31]. A survey among Turkish adults reported that adults
375 with higher trust in health professionals had more favorable attitudes towards COVID-19
376 vaccines [43]. Our survey also suggests that parents', friends', and schoolteachers' attitudes
377 toward COVID-19 vaccination may influence adolescents' willingness to get vaccinated.
378 Similarly, a diverse sample of adolescents in the United States showed that parent and peer
379 norms were distinct predictors of adolescent willingness to receive vaccines [23]. Therefore,
380 healthcare workers, parents, schoolteachers, and peers should be leveraged as advocates of
381 COVID-19 vaccines. Efforts are needed to increase vaccine acceptance among healthcare
382 workers and adult community members in general.

383 Our survey finds that, in all study areas, over 40% of adolescents considered religious
384 bodies or leaders a trusted source of information on COVID-19 vaccines and that religious
385 leaders affected COVID-19 vaccine willingness for over 20% of adolescents. There is a mixed
386 body of evidence regarding religious influence on COVID-19 vaccine perceptions. A survey
387 among Turkish adults found no significant associations between religious attitudes and COVID-

388 19 vaccine perceptions [34]. However, a survey in Pakistan showed a strong association between
389 religious inhibitions (the belief that trust in God was sufficient to protect one from infection) and
390 vaccine hesitancy in adults [36]. In our survey, for 15% of adolescents overall, vaccine
391 willingness can be affected by celebrities and social media influencers. The uncritical
392 consumption of social media may promote vaccine hesitancy [53]. In particular, emerging social
393 media platforms may be used to spread anti-vaccination content that jeopardizes vaccine uptake,
394 particularly for young people who are more likely to use such platforms [54]. Social media may
395 also spread misinformation or conspiracy theories about COVID-19. In a survey among adults in
396 Jordan, participants who believed in COVID-19 conspiracy theories were less likely to accept
397 COVID-19 vaccines [37]. Future efforts are needed to leverage religious leaders and social
398 media platforms as potential mechanisms for promoting adolescents' uptake of COVID-19
399 vaccines.

400 We report that the vaccine willingness of over 15% of adolescents in all areas is affected
401 by the vaccine's country of origin, with COVID-19 vaccines developed in the United States the
402 most accepted, followed by those developed in China; vaccines developed in Russia and India
403 appear the least accepted. Among adults in Kazakhstan [35] and Zimbabwe [27], vaccine
404 hesitancy is likewise influenced by the vaccines' country of origin or manufacturer. In
405 Kazakhstan, for instance, 78% of the respondents had the highest confidence in German-
406 produced vaccines and the lowest confidence in vaccines produced in India [35]. A global survey
407 of 19,714 adults from 17 countries showed that 52% of the respondents would only accept
408 COVID-19 vaccines from a specific country of origin [20]. In our survey, over 15% of the
409 adolescents in all areas are more willing to receive COVID-19 vaccines developed or tested in

410 Africa, highlighting the importance of technology transfer for COVID-19 vaccines to increase
411 sub-Saharan African countries' local capacities.

412 Concerns about the safety and effectiveness of COVID-19 vaccines are among the top
413 reasons for hesitancy in this survey. Accordingly, perceived lack of safety and perceived lack of
414 effectiveness strongly predict greater vaccine hesitancy. These findings align with previous
415 studies among the adult population in both high-income and low- and middle-income settings
416 [20, 31, 55]. A multi-country study assessed COVID-19 vaccine acceptance across 15 general
417 population samples, including 44,260 individuals from the United States, Russia, and 10 LMICs
418 in Asia, Africa, and South America [31]. The survey found that vaccine acceptance in LMICs is
419 primarily driven by the desire for personal protection, and the most commonly cited reason for
420 hesitancy was the concern about the side effects of the vaccine [31]. Among Chinese
421 adolescents, those who thought that COVID-19 vaccines could protect them from COVID-19
422 infection and those who believed that vaccines were safe were more likely to be willing to
423 receive COVID-19 vaccines [10]. Therefore, public health campaigns for adolescents and their
424 guardians to boost COVID-19 vaccine uptake should emphasize that the vaccines are safe for
425 adolescents and confer protection against COVID-19 infections [11].

426 We find that adolescent boys have less COVID-19 vaccine hesitancy than adolescent
427 girls, consistent with existing evidence. Among Turkish adults, males had a higher probability of
428 having positive attitudes toward COVID-19 vaccines [34]. Similarly, in a mixed-methods study
429 in Sweden, girls had higher anxiety levels about the vaccine than boys. The specific mechanisms
430 for the greater vaccine hesitancy among adolescent girls are unclear but may be related to the
431 lower tendency of risk-taking among adolescent girls than among boys (i.e., considering
432 receiving COVID-19 vaccines as a risk-taking behavior) [56]. These findings highlight the need

433 to address COVID-19 vaccine hesitancy, especially among adolescent girls. A study among
434 472,521 adults in Latin America and the Caribbean found that having depressive symptoms was
435 associated with greater fear of the adverse effects of the COVID-19 vaccines [40], indicating that
436 vaccine hesitancy for some individuals may be related to underlying mental health issues that
437 must be addressed accordingly. We do not find associations between psychological distress and
438 COVID-19 vaccine hesitancy. The impacts of the COVID-19 pandemic on the long-term mental
439 well-being of sub-Saharan African adolescents need to be investigated further.

440 The strengths of this study are the inclusion of multiple countries and cities in sub-
441 Saharan Africa and the measurement of a wide array of potential determinants of COVID-19
442 vaccine hesitancy. A potential limitation of the study was that the study areas were selected
443 based on existing connections and infrastructure, and the adolescents in each area were not
444 selected probabilistically. Therefore, the results from this study are not expected to be
445 representative of all adolescents in the country. Nevertheless, we increased the
446 representativeness of the study population by including countries and areas geographically
447 spread across sub-Saharan Africa. Therefore, the results provide important insights into the
448 levels of determinants of COVID-19 vaccine hesitancy in sub-Saharan Africa. Another limitation
449 is that, due to the nature of phone-based interviews, the adolescents included in most areas were
450 those who resided in households with access to a mobile phone. Consequently, the sample might
451 underrepresent adolescents from under-resourced households, which may affect generalizability.
452 The presence of unreachable phone numbers and failures to pick up phone calls may also have
453 impacts on the generalizability of the findings.

454 In conclusion, we show that COVID-19 vaccine hesitancy among adolescents is high
455 across the five sub-Saharan African countries, especially in Tanzania. COVID-19 vaccination

456 campaigns among sub-Saharan African adolescents must address adolescents' concerns and
457 misconceptions about COVID-19 vaccines, especially regarding vaccination safety and
458 effectiveness. It is unfortunate that, at the time of this survey, a considerable proportion of
459 adolescents in sub-Saharan Africa did not yet know when COVID-19 vaccines would become
460 available to them. It is crucial to ensure that vaccines are accessible should adolescents desire to
461 be vaccinated. It rests upon the global medical community to get the shots into the arms of the
462 often-neglected population of sub-Saharan African adolescents.

463 **Acknowledgments**

464 This work was supported by institutional support from Harvard T.H. Chan School of Public
465 Health, Boston, MA; Harvard University Center for African Studies, Boston, MA; Heidelberg
466 Institute of Global Health, Germany, and the George Washington University Milken Institute
467 School of Public Health, Washington, DC.

468

469 We thank the study participants and data collectors for making this study possible. The survey
470 team in Ghana is grateful for support from the Kintampo Health Research Centre of Ghana
471 Health Service and the community leadership of Kintampo North Municipality and Kintampo
472 South District.

473

474 **References**

- 475 1. COVID-19 Vaccines for Children and Teens: National Center for Immunization and
476 Respiratory Diseases (NCIRD), Division of Viral Diseases; 2022 [Available from:
477 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/children-teens.html>.
478 2. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al.
479 Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults:
480 A Systematic Review and Meta-analysis. *JAMA pediatrics*. 2021;175(2):143-56.
481 3. Zimet GD, Silverman RD, Fortenberry JD. Coronavirus Disease 2019 and Vaccination of
482 Children and Adolescents: Prospects and Challenges. *The Journal of pediatrics*. 2021;231:254-8.
483 4. Ng KF, Kothari T, Bandi S, Bird PW, Goyal K, Zoha M, et al. COVID-19 multisystem
484 inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection. *Journal of*
485 *medical virology*. 2020.
486 5. Idele P, Anthony D, Mofenson LM, Requejo J, You D, Luo C, et al. The evolving
487 epidemiologic and clinical picture of SARS-CoV-2 and COVID-19 disease in children and young
488 people. 2020.
489 6. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al.
490 Multisystem inflammatory syndrome in US children and adolescents. *New England Journal of*
491 *Medicine*. 2020;383(4):334-46.
492 7. Klass P, Ratner AJ. Vaccinating Children against Covid-19 — The Lessons of Measles. *The*
493 *New England journal of medicine*. 2021;384(7):589-91.
494 8. United Nations Department of Economic and Social Affairs Population Division. *World*
495 *Population Prospects 2019*, Online Edition. Rev. 1. 2019.
496 9. World Health Organization. Achieving 70% COVID-19 Immunization Coverage by Mid-
497 2022 2021 [Available from: [https://www.who.int/news/item/23-12-2021-achieving-70-covid-](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022)
498 [19-immunization-coverage-by-mid-2022](https://www.who.int/news/item/23-12-2021-achieving-70-covid-19-immunization-coverage-by-mid-2022).
499 10. Cai H, Bai W, Liu S, Liu H, Chen X, Qi H, et al. Attitudes Toward COVID-19 Vaccines in
500 Chinese Adolescents. *Frontiers in medicine*. 2021;8:691079-.
501 11. Lv M, Luo X, Shen Q, Lei R, Liu X, Liu E, et al. Safety, Immunogenicity, and Efficacy of
502 COVID-19 Vaccines in Children and Adolescents: A Systematic Review. *Vaccines (Basel)*.
503 2021;9(10):1102.
504 12. Scherer AM, Gedlinske AM, Parker AM, Gidengil CA, Askelson NM, Petersen CA, et al.
505 Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of
506 Adolescents — United States, April 15–23, 2021. *Morbidity and Mortality Weekly Report*.
507 2021;70(28):997-1003.
508 13. MacDonald NE. Vaccine hesitancy: Definition, scope and determinants. *Vaccine*.
509 2015;33(34):4161-4.
510 14. Qayum I. Top ten global health threats for 2019: the WHO list. *Journal of Rehman*
511 *Medical Institute*. 2019;5(2):01-2.
512 15. Ekwebelem OC, Yunusa I, Onyeaka H, Ekwebelem NC, Nnorom-Dike O. COVID-19 vaccine
513 rollout: will it affect the rates of vaccine hesitancy in Africa? *Public health (London)*.
514 2021;197:e18-e9.

- 515 16. Lazarus JV, Wyka K, Rauh L, Rabin K, Ratzan S, Gostin LO, et al. Hesitant or Not? The
516 Association of Age, Gender, and Education with Potential Acceptance of a COVID-19 Vaccine: A
517 Country-level Analysis. *Journal of health communication*. 2020;25(10):799-807.
- 518 17. Wake AD. The Willingness to Receive COVID-19 Vaccine and Its Associated Factors:
519 “Vaccination Refusal Could Prolong the War of This Pandemic” – A Systematic Review. *Risk*
520 *management and healthcare policy*. 2021;14:2609-23.
- 521 18. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of
522 Vaccine Acceptance Rates. *Vaccines (Basel)*. 2021;9(2):160.
- 523 19. Wake AD. The Acceptance Rate Toward COVID-19 Vaccine in Africa: A Systematic
524 Review and Meta-analysis. *Global pediatric health*. 2021;8:2333794-X211048738.
- 525 20. Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, et al. COVID-19 vaccination
526 intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17
527 countries. *Infectious diseases of poverty*. 2021;10(1):1-122.
- 528 21. Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of
529 potential acceptance of a COVID-19 vaccine. *Nature medicine*. 2021;27(2):225-8.
- 530 22. Willis DE, Presley J, Williams M, Zaller N, McElfish PA. COVID-19 vaccine hesitancy
531 among youth. *Human vaccines & immunotherapeutics*. ahead-of-print(ahead-of-print):1-3.
- 532 23. Rogers AA, Cook RE, Button JA. Parent and Peer Norms are Unique Correlates of COVID-
533 19 Vaccine Intentions in a Diverse Sample of U.S. Adolescents. *Journal of adolescent health*.
534 2021.
- 535 24. Afifi TO, Salmon S, Taillieu T, Stewart-Tufescu A, Fortier J, Driedger SM. Older
536 adolescents and young adults willingness to receive the COVID-19 vaccine: Implications for
537 informing public health strategies. *Vaccine*. 2021;39(26):3473-9.
- 538 25. Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, et al.
539 To be or not to be vaccinated against COVID-19 – The adolescents’ perspective – A mixed-
540 methods study in Sweden. *Vaccine: X*. 2021;9:100117-.
- 541 26. Carcelen AC, Prospero C, Mutembo S, Chongwe G, Mwansa FD, Ndubani P, et al. COVID-
542 19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19
543 vaccination rollout in sub-Saharan Africa. *Human vaccines & immunotherapeutics*. ahead-of-
544 print(ahead-of-print):1-6.
- 545 27. McAbee L, Tapera O, Kanyangarara M. Factors Associated with COVID-19 Vaccine
546 Intentions in Eastern Zimbabwe: A Cross-Sectional Study. *Vaccines (Basel)*. 2021;9(10):1109.
- 547 28. Echoru I, Ajambo PD, Keirania E, Bukenya EEM. Sociodemographic factors associated
548 with acceptance of COVID-19 vaccine and clinical trials in Uganda: a cross-sectional study in
549 western Uganda. *BMC public health*. 2021;21(1):1106-.
- 550 29. Dinga JN, Sinda LK, Titanji VPK. Assessment of Vaccine Hesitancy to a COVID-19 Vaccine
551 in Cameroonian Adults and Its Global Implication. *Vaccines (Basel)*. 2021;9(2):175.
- 552 30. Acheampong T, Akorsikumah EA, Osa-Kwapong J, Khalid M, Appiah A, Amuasi JH.
553 Examining Vaccine Hesitancy in Sub-Saharan Africa: A Survey of the Knowledge and Attitudes
554 among Adults to Receive COVID-19 Vaccines in Ghana. *Vaccines (Basel)*. 2021;9(8):814.
- 555 31. Solís Arce JS, Warren SS, Meriggi NF, Scacco A, McMurry N, Voors M, et al. COVID-19
556 vaccine acceptance and hesitancy in low- and middle-income countries. *Nature medicine*.
557 2021;27(8):1385-94.

- 558 32. Adebisi YA, Alaran AJ, Bolarinwa OA, Akande-Sholabi W, Lucero-Prisno Iii DE. When it is
559 available, will we take it? Social media users' perception of hypothetical COVID-19 vaccine in
560 Nigeria. *The Pan African medical journal*. 2021;38:230-.
- 561 33. Harapan H, Wagner AL, Yufika A, Winardi W, Anwar S, Gan AK, et al. Acceptance of a
562 COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. *Frontiers in public
563 health*. 2020;8:381-.
- 564 34. Kilic M, Ustundag Ocal N, Uslukilic G. The relationship of Covid-19 vaccine attitude with
565 life satisfaction, religious attitude and Covid-19 avoidance in Turkey. *Human vaccines &
566 immunotherapeutics*. 2021;17(10):3384-93.
- 567 35. Issanov A, Akhmetzhanova Z, Riethmacher D, Aljofan M. Knowledge, attitude, and
568 practice toward COVID-19 vaccination in Kazakhstan: a cross-sectional study. *Human vaccines &
569 immunotherapeutics*. 2021;17(10):3394-400.
- 570 36. Ahmed TF, Ahmed A, Ahmed S, Ahmed HU. Understanding COVID-19 vaccine
571 acceptance in Pakistan: an echo of previous immunizations or prospect of change? *Expert
572 review of vaccines*. 2021;20(9):1185-93.
- 573 37. El-Elimat T, AbuAlSamen MM, Almomani BA, Al-Sawalha NA, Alali FQ. Acceptance and
574 attitudes toward COVID-19 vaccines: A cross-sectional study from Jordan. *PloS one*.
575 2021;16(4):e0250555-e.
- 576 38. Bagateli LE, Saeki EY, Fadda M, Agostoni C, Marchisio P, Milani GP. COVID-19 Vaccine
577 Hesitancy among Parents of Children and Adolescents Living in Brazil. *Vaccines (Basel)*.
578 2021;9(10):1115.
- 579 39. Abdulah DM. Prevalence and correlates of COVID-19 vaccine hesitancy in the general
580 public in Iraqi Kurdistan: A cross-sectional study. *Journal of medical virology*. 2021;93(12):6722-
581 31.
- 582 40. Urrunaga-Pastor D, Bendezu-Quispe G, Herrera-Añazco P, Uyen-Cateriano A, Toro-
583 Huamanchumo CJ, Rodriguez-Morales AJ, et al. Cross-sectional analysis of COVID-19 vaccine
584 intention, perceptions and hesitancy across Latin America and the Caribbean. *Travel medicine
585 and infectious disease*. 2021;41:102059-.
- 586 41. Elhadi M, Alsoufi A, Alhadi A, Hmeida A, Alshareea E, Dokali M, et al. Knowledge,
587 attitude, and acceptance of healthcare workers and the public regarding the COVID-19 vaccine:
588 a cross-sectional study. *BMC public health*. 2021;21(1):955-.
- 589 42. Kumari A, Ranjan P, Chopra S, Kaur D, Kaur T, Kalanidhi KB, et al. What Indians Think of
590 the COVID-19 vaccine: A qualitative study comprising focus group discussions and thematic
591 analysis. *Diabetes & metabolic syndrome clinical research & reviews*. 2021;15(3):679-82.
- 592 43. Karabela ŞN, Coşkun F, Hoşgör H. Investigation of the relationships between perceived
593 causes of COVID-19, attitudes towards vaccine and level of trust in information sources from
594 the perspective of Infodemic: the case of Turkey. *BMC public health*. 2021;21(1):1195-.
- 595 44. Hervish A, Clifton D. adolescents and Young people in Sub-Saharan Africa: opportunities
596 and challenges: UNFPA; 2012.
- 597 45. Hemler EC, Korte ML, Lankoande B, Millogo O, Assefa N, Chukwu A, et al. Design and
598 Field Methods of the ARISE Network COVID-19 Rapid Monitoring Survey. *The American journal
599 of tropical medicine and hygiene*. 2021;105(2):310.

- 600 46. Darling AM, Assefa N, Bärnighausen T, Berhane Y, Canavan CR, Guwatudde D, et al.
601 Design and field methods of the ARISE Network Adolescent Health Study. *Tropical Medicine &*
602 *International Health*. 2020;25(1):5-14.
- 603 47. Leyna GH, Berkman LF, Njelekela MA, Kazonda P, Irema K, Fawzi W, et al. Profile: the
604 Dar Es Salaam health and demographic surveillance system (Dar es Salaam HDSS). *International*
605 *Journal of Epidemiology*. 2017;46(3):801-8.
- 606 48. Wang D, Chukwu A, Millogo O, Assefa N, James C, Young T, et al. The COVID-19
607 Pandemic and Adolescents' Experience in Sub-Saharan Africa: A Cross-Country Study Using a
608 Telephone Survey. *The American journal of tropical medicine and hygiene*. 2021;105(2):331-41.
- 609 49. Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety and
610 depression: the PHQ-4. *Psychosomatics*. 2009;50(6):613-21.
- 611 50. Zou G. A modified poisson regression approach to prospective studies with binary data.
612 *American journal of epidemiology*. 2004;159(7):702-6.
- 613 51. Makoni M. Tanzania refuses COVID-19 vaccines. *The Lancet (British edition)*.
614 2021;397(10274):566-.
- 615 52. Buguzi S. Covid-19: Counting the cost of denial in Tanzania. *BMJ (Online)*.
616 2021;373:n1052-n.
- 617 53. Allington D, McAndrew S, Moxham-Hall VL, Duffy B. Media usage predicts intention to
618 be vaccinated against SARS-CoV-2 in the US and the UK. *Vaccine*. 2021;39(18):2595-603.
- 619 54. Basch CH, Meleo-Erwin Z, Fera J, Jaime C, Basch CE. A global pandemic in the time of
620 viral memes: COVID-19 vaccine misinformation and disinformation on TikTok. *Human vaccines*
621 *& immunotherapeutics*. 2021;17(8):2373-7.
- 622 55. Bono SA, Faria de Moura Villela E, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors
623 Affecting COVID-19 Vaccine Acceptance: An International Survey among Low-and Middle-
624 Income Countries. *Vaccines (Basel)*. 2021;9(5):515.
- 625 56. Reniers RLEP, Murphy L, Lin A, Bartolome SP, Wood SJ. Risk Perception and Risk-Taking
626 Behaviour during Adolescence: The Influence of Personality and Gender. *PloS one*.
627 2016;11(4):e0153842-e.

629 **Supporting information**

630 **S1 Table. Trusted information sources and expectations about the COVID-19 vaccine among adolescents**

631 **in a phone-based survey in five sub-Saharan African countries, 2021**

632

633

634